Corticosteroid Use in Pneumonia

Introduction to Corticosteroid Therapy

The American College of Critical Care Medicine recommends the use of corticosteroids as adjunctive therapy for hospitalized adults with severe community-acquired pneumonia (CAP), specifically hydrocortisone <400 mg/day IV or equivalent for 5-7 days, with a conditional recommendation and moderate-quality evidence showing reduced mortality (RR 0.67) and shortened hospital stay (mean difference -2.96 days) 1
The American Thoracic Society and Infectious Diseases Society of America provide a strong recommendation against routine corticosteroid use in non-severe CAP based on high-quality evidence showing no mortality benefit and only marginal improvements in time to clinical stability 2

For severe CAP, the Society of Critical Care Medicine and European Society of Intensive Care Medicine provide a conditional recommendation with moderate-quality evidence showing reduced mortality (RR 0.67), shortened hospital stay (mean difference -2.96 days), reduced need for mechanical ventilation (RR 0.45), and prevention of ARDS (RR 0.24) with corticosteroid therapy 1
A 2024 meta-analysis found hydrocortisone reduced mortality by 52% (RR 0.48) in severe CAP 1

For patients who develop moderate-to-severe ARDS secondary to pneumonia, the American Thoracic Society suggests corticosteroids with a conditional recommendation and moderate certainty, showing probable mortality reduction (RR 0.84) and reduced mechanical ventilation duration (mean difference -4 days) 4
Corticosteroids should not be used in influenza pneumonia due to increased mortality risk, with a meta-analysis showing an odds ratio of dying of 3.06 with corticosteroid use 1

Hyperglycemia is the most common complication, occurring in approximately 50% more patients (RR 1.72), and blood glucose should be monitored closely during treatment 1
No significant increase in secondary infections (RR 1.19), gastrointestinal bleeding (RR 1.20), or neuromuscular weakness (RR 0.85) with short-course, low-dose therapy 4

The maximum recommended duration of corticosteroid therapy is 7 days to minimize adverse effects while maintaining efficacy, with doses >400 mg hydrocortisone equivalent daily not recommended 1
Prolonged courses (>4 weeks at ≥20 mg methylprednisolone equivalent) require Pneumocystis prophylaxis consideration, although this guideline is from Praxis Medical Insights and thus not preferred 5